XLH kids may get lower drug doses without losing control
NCT ID NCT07183579
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 33 times
Summary
This study looks back at medical records of about 120 children with X-linked hypophosphatemia (XLH) who have been taking burosumab for at least a year. The goal is to see if starting with a lower dose than the standard 0.8 mg/kg can still keep blood phosphate levels in a healthy range. If so, some children may avoid unnecessarily high doses and their side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nottingham University Hospitals NHS Trust
RECRUITINGNottingham, NG7 2UH, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.